Marginal zone lymphoma - historical
Revision as of 12:14, 4 July 2023 by Warner-admin (talk | contribs) (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1")
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main MZL regimen page to find other regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Umbralisib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Fowler et al. 2021 (UNITY-NHL) | 2017-2018 | Phase 2b (RT) |
Targeted therapy
- Umbralisib (Ukoniq) 800 mg PO once per day
Continued indefinitely
References
- UNITY-NHL: Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. link to original article link to PMC article PubMed NCT02793583